Guy Laurent
Service d'Urologie, CHU, Clermont-Ferrand.
Bull Cancer. 2007 Jul;94(7 Suppl):F15-20.
Treatment of prostate cancer with a high risk of recurrence following local treatment (surgery or radiotherapy) remains a controversial subject. Adjuvant treatment must be scheduled if there are factors for a poor prognosis from the anatomopathologic results of biopsies or the excised prostate. The aim of this treatment is to destroy any remaining tumour cells after curative treatment. In a review of the literature, one can note the various adjuvant treatments according to their indications. A benefit has been demonstrated for adjuvant radiotherapy following radical prostatectomy with capsular invasion or positive margins. This is of interest in terms of survival with biological recurrence. However, no study has demonstrated a benefit in terms of overall survival. Following curative radiotherapy, there is also a specific benefit of adjuvant hormonal therapy. This benefit consists of a significant improvement in survival without progression, specific survival and overall survival. All in all, it would appear that patients with a high risk of progression who were initially treated by radiotherapy or radical prostatectomy can benefit from the adjuvant therapeutic alternatives that have demonstrated their interest. The decision to perform adjuvant treatment following curative treatment should be discussed at weekly interdisciplinary meetings.
局部治疗(手术或放疗)后复发风险高的前列腺癌的治疗仍是一个有争议的话题。如果活检或切除前列腺的解剖病理结果显示存在预后不良因素,则必须安排辅助治疗。这种治疗的目的是在根治性治疗后消灭任何残留的肿瘤细胞。在对文献的综述中,可以根据其适应症注意到各种辅助治疗方法。对于根治性前列腺切除术后出现包膜侵犯或切缘阳性的患者,辅助放疗已显示出益处。这在生物性复发的生存方面具有重要意义。然而,没有研究表明在总生存方面有获益。在根治性放疗后,辅助激素治疗也有特定益处。这种益处包括无进展生存期、特定生存期和总生存期的显著改善。总而言之,最初接受放疗或根治性前列腺切除术的高进展风险患者似乎可以从已证明其价值的辅助治疗选择中获益。根治性治疗后是否进行辅助治疗的决定应在每周的多学科会议上进行讨论。